Peringatan Keamanan

Studies related to acute and chronic toxicity as well as teratogenesis and fertility has proven that dihydroergocristine is a non-toxic and very well tolerated drug.A32880 To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit DB01049.

Dihydroergocristine

DB13345

small molecule approved experimental

Deskripsi

Dihydroergocristine is part of the ergoloid mixture products.L2637 It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline.A32879 To know more about ergoloid mixtures, please visit DB01049.

Struktur Molekul 2D

Berat 611.743
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half-life of dihydroergocristine has only been studied as part of the therapeutic mixture, please refer to [DB01049].
Volume Distribusi Dihydroergocristine presents a large volume of distribution of 52 l/kg.[A32911] To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit [DB01049].
Klirens (Clearance) Dihydroergocristine presents a high systemic clearance rate of 2.65 l/h.hg.[A32911] To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit [DB01049].

Absorpsi

Dihydroergocristine presents an absorption in the digestive tract of about 25% of the administered dose. When dihydroergocristine was orally administered in humans and the peak plasma concentration of 0.28 mcg/l was achieved after 0.46 hours. In the same report, the AUC was reported to be 0.39 mcg/l.h.A32881 To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit DB01049.

Metabolisme

The major metabolite of dihydroergocristine is 8'-hydroxy-dihydroergocristine is produced in the liver.A32881 The modification of dihydroergocristine in the body is very extensive and it has been observed as an almost complete absence of the unchanged drug.A32911 To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit DB01049.

Rute Eliminasi

The most important elimination route of dihydroergocristine is in via the bile and it accounts for over 85% of the eliminated dose. Urine elimination accounts only for 5% of the administered dose.A32907 To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit DB01049.

Interaksi Obat

1032 Data
Troglitazone Troglitazone may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.
Progesterone Progesterone may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.
Chlorpromazine Chlorpromazine may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.
Celecoxib Celecoxib may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.
Cimetidine Cimetidine may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.
Bosentan Bosentan may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.
Ethinylestradiol Ethinylestradiol may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.
Glyburide Glyburide may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.
Ursodeoxycholic acid Ursodeoxycholic acid may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.
Cholic Acid Cholic Acid may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.
Fusidic acid Fusidic acid may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.
Simeprevir Simeprevir may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.
Lenvatinib Lenvatinib may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.
Letermovir The metabolism of Dihydroergocristine can be decreased when combined with Letermovir.
Valinomycin Valinomycin may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.
Olmesartan Olmesartan may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.
Pralsetinib Pralsetinib may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.
Phenytoin The metabolism of Dihydroergocristine can be increased when combined with Phenytoin.
Fosphenytoin The metabolism of Dihydroergocristine can be increased when combined with Fosphenytoin.
Valsartan Dihydroergocristine may decrease the antihypertensive activities of Valsartan.
Ramipril Dihydroergocristine may decrease the antihypertensive activities of Ramipril.
Remikiren Dihydroergocristine may decrease the antihypertensive activities of Remikiren.
Torasemide Dihydroergocristine may decrease the antihypertensive activities of Torasemide.
Guanadrel Dihydroergocristine may decrease the antihypertensive activities of Guanadrel.
Chlorthalidone Dihydroergocristine may decrease the antihypertensive activities of Chlorthalidone.
Nitroprusside Dihydroergocristine may decrease the antihypertensive activities of Nitroprusside.
Minoxidil Dihydroergocristine may decrease the antihypertensive activities of Minoxidil.
Treprostinil Dihydroergocristine may decrease the antihypertensive activities of Treprostinil.
Bendroflumethiazide Dihydroergocristine may decrease the antihypertensive activities of Bendroflumethiazide.
Prazosin Dihydroergocristine may decrease the antihypertensive activities of Prazosin.
Fosinopril Dihydroergocristine may decrease the antihypertensive activities of Fosinopril.
Trandolapril Dihydroergocristine may decrease the antihypertensive activities of Trandolapril.
Metolazone Dihydroergocristine may decrease the antihypertensive activities of Metolazone.
Benazepril Dihydroergocristine may decrease the antihypertensive activities of Benazepril.
Cyclothiazide Dihydroergocristine may decrease the antihypertensive activities of Cyclothiazide.
Candoxatril Dihydroergocristine may decrease the antihypertensive activities of Candoxatril.
Mecamylamine Dihydroergocristine may decrease the antihypertensive activities of Mecamylamine.
Moexipril Dihydroergocristine may decrease the antihypertensive activities of Moexipril.
Lisinopril Dihydroergocristine may decrease the antihypertensive activities of Lisinopril.
Metyrosine Dihydroergocristine may decrease the antihypertensive activities of Metyrosine.
Hydroflumethiazide Dihydroergocristine may decrease the antihypertensive activities of Hydroflumethiazide.
Cryptenamine Dihydroergocristine may decrease the antihypertensive activities of Cryptenamine.
Perindopril Dihydroergocristine may decrease the antihypertensive activities of Perindopril.
Candesartan cilexetil Dihydroergocristine may decrease the antihypertensive activities of Candesartan cilexetil.
Fenoldopam Dihydroergocristine may decrease the antihypertensive activities of Fenoldopam.
Eprosartan Dihydroergocristine may decrease the antihypertensive activities of Eprosartan.
Chlorothiazide Dihydroergocristine may decrease the antihypertensive activities of Chlorothiazide.
Quinapril Dihydroergocristine may decrease the antihypertensive activities of Quinapril.
Hydrochlorothiazide Dihydroergocristine may decrease the antihypertensive activities of Hydrochlorothiazide.
Trichlormethiazide Dihydroergocristine may decrease the antihypertensive activities of Trichlormethiazide.
Deserpidine Dihydroergocristine may decrease the antihypertensive activities of Deserpidine.
Pentolinium Dihydroergocristine may decrease the antihypertensive activities of Pentolinium.
Trimethaphan Dihydroergocristine may decrease the antihypertensive activities of Trimethaphan.
Diazoxide Dihydroergocristine may decrease the antihypertensive activities of Diazoxide.
Bretylium Dihydroergocristine may decrease the antihypertensive activities of Bretylium.
Terazosin Dihydroergocristine may decrease the antihypertensive activities of Terazosin.
Captopril Dihydroergocristine may decrease the antihypertensive activities of Captopril.
Epoprostenol Dihydroergocristine may decrease the antihypertensive activities of Epoprostenol.
Polythiazide Dihydroergocristine may decrease the antihypertensive activities of Polythiazide.
Cilazapril Dihydroergocristine may decrease the antihypertensive activities of Cilazapril.
Saprisartan Dihydroergocristine may decrease the antihypertensive activities of Saprisartan.
Spirapril Dihydroergocristine may decrease the antihypertensive activities of Spirapril.
Tienilic acid Dihydroergocristine may decrease the antihypertensive activities of Tienilic acid.
Debrisoquine Dihydroergocristine may decrease the antihypertensive activities of Debrisoquine.
Diethylnorspermine Dihydroergocristine may decrease the antihypertensive activities of Diethylnorspermine.
Temocapril Dihydroergocristine may decrease the antihypertensive activities of Temocapril.
Hexamethonium Dihydroergocristine may decrease the antihypertensive activities of Hexamethonium.
Trimazosin Dihydroergocristine may decrease the antihypertensive activities of Trimazosin.
Nicorandil Dihydroergocristine may decrease the antihypertensive activities of Nicorandil.
Rauwolfia serpentina root Dihydroergocristine may decrease the antihypertensive activities of Rauwolfia serpentina root.
Enalaprilat Dihydroergocristine may decrease the antihypertensive activities of Enalaprilat.
Angiotensin 1-7 Dihydroergocristine may decrease the antihypertensive activities of Angiotensin 1-7.
Imidapril Dihydroergocristine may decrease the antihypertensive activities of Imidapril.
BQ-123 Dihydroergocristine may decrease the antihypertensive activities of BQ-123.
Cicletanine Dihydroergocristine may decrease the antihypertensive activities of Cicletanine.
Dihydralazine Dihydroergocristine may decrease the antihypertensive activities of Dihydralazine.
Zofenopril Dihydroergocristine may decrease the antihypertensive activities of Zofenopril.
Guanoxan Dihydroergocristine may decrease the antihypertensive activities of Guanoxan.
Delapril Dihydroergocristine may decrease the antihypertensive activities of Delapril.
Vincamine Dihydroergocristine may decrease the antihypertensive activities of Vincamine.
Linsidomine Dihydroergocristine may decrease the antihypertensive activities of Linsidomine.
Guanoxabenz Dihydroergocristine may decrease the antihypertensive activities of Guanoxabenz.
Tolonidine Dihydroergocristine may decrease the antihypertensive activities of Tolonidine.
Endralazine Dihydroergocristine may decrease the antihypertensive activities of Endralazine.
Cadralazine Dihydroergocristine may decrease the antihypertensive activities of Cadralazine.
Cyclopenthiazide Dihydroergocristine may decrease the antihypertensive activities of Cyclopenthiazide.
Bietaserpine Dihydroergocristine may decrease the antihypertensive activities of Bietaserpine.
Guanazodine Dihydroergocristine may decrease the antihypertensive activities of Guanazodine.
Methoserpidine Dihydroergocristine may decrease the antihypertensive activities of Methoserpidine.
Guanoclor Dihydroergocristine may decrease the antihypertensive activities of Guanoclor.
Muzolimine Dihydroergocristine may decrease the antihypertensive activities of Muzolimine.
Xipamide Dihydroergocristine may decrease the antihypertensive activities of Xipamide.
Candesartan Dihydroergocristine may decrease the antihypertensive activities of Candesartan.
Tocopherylquinone Dihydroergocristine may decrease the antihypertensive activities of Tocopherylquinone.
Benazeprilat Dihydroergocristine may decrease the antihypertensive activities of Benazeprilat.
Fosinoprilat Dihydroergocristine may decrease the antihypertensive activities of Fosinoprilat.
Ramiprilat Dihydroergocristine may decrease the antihypertensive activities of Ramiprilat.
Perindoprilat Dihydroergocristine may decrease the antihypertensive activities of Perindoprilat.
Quinaprilat Dihydroergocristine may decrease the antihypertensive activities of Quinaprilat.
Furosemide Dihydroergocristine may decrease the antihypertensive activities of Furosemide.

Target Protein

Serotonin Receptors HTR1A
Alpha-2C adrenergic receptor ADRA2C
Beta adrenergic receptor ADRB1
Alpha adrenergic receptor ADRA1A
Dopamine receptor DRD1

Referensi & Sumber

Artikel (PubMed)
  • PMID: 3147464
    Drago F, Valerio C, Scalisi B, D'Agata V, Scapagnini U: Dihydroergocristine and memory alterations of aged male rats. Pharmacol Biochem Behav. 1988 Aug;30(4):961-5.
  • PMID: 1492857
    Coppi G: Dihydroergocristine. A review of pharmacology and toxicology. Arzneimittelforschung. 1992 Nov;42(11A):1381-90.
  • PMID: 16379666
    Bicalho B, Guzzo GC, Lilla S, Dos Santos HO, Mendes GD, Caliendo G, Perissutti E, Aiello A, Luciano P, Santagada V, Pereira AS, De Nucci G: Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma. Curr Drug Metab. 2005 Dec;6(6):519-29.
  • PMID: 26567970
    Lei X, Yu J, Niu Q, Liu J, Fraering PC, Wu F: The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer's disease amyloid-beta peptides. Sci Rep. 2015 Nov 16;5:16541. doi: 10.1038/srep16541.
  • PMID: 1271240
    Nimmerfall F, Rosenthaler J: Ergot alkaloids: hepatic distribution and estimation of absorption by measurement of total radioactivity in bile and urine. J Pharmacokinet Biopharm. 1976 Feb;4(1):57-66.
  • PMID: 1492859
    Grognet JM, Riviere R, Istin M, Zanotti A, Coppi G: The pharmacokinetics of dihydroergocristine after intravenous and oral administration in rats. Arzneimittelforschung. 1992 Nov;42(11A):1394-6.

Contoh Produk & Brand

Produk: 6 • International brands: 1
Produk
  • Ergoloid Mesylates
    Tablet • - • Oral • US • Generic • Approved
  • Ergoloid Mesylates
    Tablet • - • Oral • US • Generic • Approved
  • Ergoloid Mesylates
    Tablet • - • Oral • US • Generic • Approved
  • Ergoloid Mesylates
    Tablet • - • Oral • US • Generic • Approved
  • Ergoloid Mesylates
    Tablet • - • Oral • US • Generic • Approved
  • Ergoloid Mesylates
    Tablet, orally disintegrating • - • Oral • US • Generic • Approved
International Brands
  • Iskevert — Medley S/A

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul